ArticleEuropean journal of nuclear medicine and molecular imaging2022
Efficacy and safety of
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- The therapeutic efficacy ofFrontiers in oncology · 2025Pooled it
- Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Future scenarios of radioligand therapy in pheochromocytomas and paragangliomas.EJNMMI reports · 2026Review
- Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [European journal of nuclear medicine and molecular imaging · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.Endocrine-related cancer · 2026Review
- Macrocyclic and Hydroxamate Ligands forInorganic chemistry · 2026Article
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025Review
- Measurement ofACS omega · 2025Article
- Clinical perspective on targeted alpha therapy usingAnnals of nuclear medicine · 2025Review
- Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.Future oncology (London, England) · 2025Review
- Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2025Review
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
- Long-Term Therapeutic Effects ofPharmaceutics · 2024Article
- Radioligand therapies in meningioma: Evidence and future directions.Neuro-oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we aim to evaluate the efficacy and safety of
methodsNine (6 males and 3 females) consecutive patients with histologically proven PGLs were treated with
resultsFollowing
conclusionThe evidence from this study suggests
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.